145 results on '"Patrick, Katharine"'
Search Results
2. FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
3. Use of eculizumab in children with allogeneic haematopoietic stem cell transplantation associated thrombotic microangiopathy - a multicentre retrospective PDWP and IEWP EBMT study
4. T-cell replete cord transplants give superior outcomes in high-risk and relapsed/refractory pediatric myeloid malignancy
5. Alemtuzumab, Dual Graft-versus-Host Disease Prophylaxis, and Lower CD3+ T Cell Doses Equalize Rates of Acute and Chronic Graft-versus-Host Disease in Pediatric Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation with Matched Unrelated Donor Peripheral Blood Stem Cells or Bone Marrow Grafts
6. EARLY RELAPSE DETECTION IN JMML PATIENTS FOLLOWING HAEMATOPOIETIC STEM CELL TRANSPLANT
7. Treosulfan–fludarabine–thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies
8. Gonadal Function after Busulfan Compared with Treosulfan in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplant
9. Allogeneic HSCT for classical BCR::ABL1-negative myeloproliferative neoplasms in children: the retrospective study of the EBMT Pediatric Diseases WP
10. Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL
11. OC 12 - EARLY RELAPSE DETECTION IN JMML PATIENTS FOLLOWING HAEMATOPOIETIC STEM CELL TRANSPLANT
12. High transplant-related mortality associated with haematopoietic stem cell transplantation for paediatric therapy-related acute myeloid leukaemia (t-AML). A study on behalf of the United Kingdom Paediatric Blood and Bone Marrow Transplant Group
13. T-Cell Replete Unrelated Cord Blood Transplant Give Superior Outcomes to Other Donor Sources in High Risk and Relapsed/Refractory Paediatric Myeloid Malignancy
14. The Impact of Pre-Transplant Extramedullary Disease on the Outcome of Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Children- on Behalf of PDWP/EBMT
15. High Molecular Response Rate and Overall Survival with FLT3 Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML
16. Reduced Intensity Reinduction Followed By Blinatumomab Achieves Excellent MRD Clearance with Reduced Toxicity and Facilitates Timely Transplant in Children and Young People with Relapsed B-Precursor Acute Lymphoblastic Leukemia
17. Blinatumomab As Toxicity Sparing First Line Treatment of Children and Young Persons with B-Precursor Acute Lymphoblastic Leukaemia (B-ALL)
18. Use of eculizumab in children with allogeneic haematopoietic stem cell transplantation associated thrombotic microangiopathy - a multicentre retrospective PDWP and IEWP EBMT study
19. FLT3inhibitors as MRD-guided salvage treatment for molecular failure in FLT3mutated AML
20. Armaments and security : the basis of British policy at the Disarmament Conference, 1931-1933
21. Granulocytes to Induce Donor-Derived T Cell Expansion after T Replete, Mismatched CB in Post-Transplant Relapsed and Refractory Paediatric Acute Leukaemia: Results of Grans Trial.
22. During CB Transplant in MRD-Positive AML, Relapse is Usually Early, is Reduced by Acute GVHD and is Influenced by Ciclosporin Exposure: A Multicenter National Experience.
23. The yield of monitoring for HSV and VZV viremia in pediatric hematopoietic stem cell transplant patients
24. Outcomes of Paediatric Acute Promyelocytic Leukaemia in the UK
25. Allogeneic Hematopoietic Stem Cell Transplantation for BCR/ABL1-Negative Myeloproliferative Neoplasms in Children - Retrospective Report on Behalf of I-BFM SCT Committee and EBMT Pediatric Diseases WP
26. Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003
27. Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol
28. Abstract 24: Granulocytes to Induce Donor-Derived T Cell Expansion after T Replete, Mismatched CB in Post-Transplant Relapsed and Refractory Paediatric Acute Leukaemia: Results of Grans Trial
29. Abstract 25: During CB Transplant in MRD-Positive AML, Relapse is Usually Early, is Reduced by Acute GVHD and is Influenced by Ciclosporin Exposure: A Multicenter National Experience
30. Long term lympho-haematopoietic reconstitution by umbilical cord blood stem cells following primary graft failure and autologous rescue
31. Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemia
32. Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL‐class fusion
33. Blinatumomab for infant acute lymphoblastic leukemia
34. Mixed chimerism post haematopoietic stem cell transplantation in JMML: Interventions and outcome.
35. Noonan syndrome associated with bleeding disorders
36. Molecular MRD Monitoring Is Feasible in the Majority of Children with AML and Is Highly Predictive of Outcome: Results from the International MyeChild01 Study
37. Excellent overall and chronic graft‐versus‐host‐disease‐free event‐free survival in Fanconi anaemia patients undergoing matched related‐ and unrelated‐donor bone marrow transplantation using alemtuzumab–Flu–Cy: the UK experience
38. Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant
39. High Molecular Response Rate and Overall Survival with FLT3Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML
40. Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of EBMT group.
41. Prospective Clinical Phase II Results on Treosulfan-Based Conditioning Treatment of 70 Paediatric Patients with Haematological Malignancies
42. Prognostic impact of the absence of biallelic deletion at the TRG locus for pediatric patients with T-cell acute lymphoblastic leukemia treated on the Medical Research Council UK Acute Lymphoblastic Leukemia 2003 trial
43. Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia
44. Alemtuzumab, Dual Graft-versus-Host Disease Prophylaxis, and Lower CD3+T Cell Doses Equalize Rates of Acute and Chronic Graft-versus-Host Disease in Pediatric Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation with Matched Unrelated Donor Peripheral Blood Stem Cells or Bone Marrow Grafts
45. Update on biology and treatment of T-cell acute lymphoblastic leukaemia
46. Improved Outcome for Children and Young People with T-Acute Lymphoblastic Leukaemia: Results of the UKALL 2003 Trial
47. Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia.
48. Characteristics and Outcomes Of Patients With Down Syndrome Associated Acute Lymphoblastic Leukaemia Treated On UKALL 2003
49. Characteristics and Outcome Of Children and Young Adults With Early T-Precusor (ETP) ALL Treated On UKALL 2003
50. Real‐world use of venetoclax in the treatment of paediatric and teenage/young adult haematological malignancies.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.